Takeda China and OrigiMed Announce Strategic Collaboration to Accelerate Oncology Drug Development and Commercialization

On November 8, 2020, at the Third China International Import Expo, Takeda (China) Investment Co., Ltd. (“Takeda China”) and OrigiMed INC (“OrigiMed”) announced a strategic partnership. By leveraging their respective strengths through complementary advantages, the two parties will fully utilize their capabilities in the field of oncology drugs to build an innovative integrated diagnosis and treatment platform, jointly advancing the research and development and commercialization of innovative oncology drugs.

Mr. Shan Guohong, President of Takeda China; Dr. Chen Jie, Head of Medical Affairs at Takeda China; Dr. Wang Kai, CEO of OrigiMed; and Ms. Zhao Ping, Vice President of OrigiMed, jointly attended the strategic cooperation signing ceremony between Takeda China and OrigiMed. The strategic partnership between Takeda China and OrigiMed will maximize the strengths of both parties, conduct in-depth collaborative exploration in the field of oncology treatment, establish an innovative integrated diagnosis and treatment platform, and jointly commit to collaborations related to new drug development. Takeda China will fully leverage its R&D innovation capabilities in oncology, continue to enrich its robust pipeline of anti-tumor drugs, improve the accessibility of innovative medicines for patients in China, and better address the unmet medical needs of Chinese patients. OrigiMed, centered on its vast accumulated data and built upon its superior second-generation sequencing technology, will drive innovation in new drug development and precision diagnosis and treatment through data-driven approaches. It will provide Takeda China with more comprehensive and precise molecular testing technologies and a “one-stop” holistic commercialization solution in the field of anti-tumor new drug development, thereby accelerating Takeda China’s new drug R&D process and delivering survival benefits to more patients in China.

Takeda Pharmaceutical Company Limited is a global, research-and-development-driven biopharmaceutical company that is patient-centric and values-based.Takeda focuses on drug research and development in four core therapeutic areas: oncology, gastroenterology, neuroscience, and rare diseases. It also makes targeted R&D investments in specialized fields such as plasma-derived therapies and vaccines, boasting a robust pipeline of innovative molecular entities. With extensive experience in new drug development and commercialization, Takeda plans to launch more than 15 innovative drugs in China over the next five years, benefiting 10 million Chinese patients and positioning itself as one of the multinational pharmaceutical companies with the highest number of new product launches in the country.

As a leading precision oncology company in China, OrigiMed is committed to providing pharmaceutical companies with precise, customizable, and fully traceable end-to-end solutions.OrigiMed boasts CLIA- and CAP-accredited laboratories that meet international standards, along with extensive experience in collaborating with multinational pharmaceutical companies. By leveraging its advantages in data integration and molecular testing technologies, OrigiMed provides comprehensive, end-to-end “one-stop” solutions for the research, development, and market launch of anti-tumor drugs and companion diagnostics. The company is committed to enhancing access to high-quality medical resources and actively driving innovation in clinical cancer treatment in China.

Mr. Shan Guohong, Global Senior Vice President of Takeda Pharmaceutical Company Limited and President of Takeda China, stated: “Takeda looks forward to growing and developing alongside Chinese enterprises through its collaboration with OrigiMed, developing more internationally cutting-edge innovative products and technologies, expanding access to medicines to benefit more patients, and contributing to the realization of the ‘Healthy China’ vision.”

Dr. Wang Kai, Founder and CEO of OrigiMed, stated, “Takeda is a company with a rich history spanning over 200 years and stands as the largest biopharmaceutical company in Asia and among the top ten globally. We are delighted to establish a strategic partnership with Takeda China. OrigiMed looks forward to collaborating with Takeda to leverage cutting-edge technologies such as next-generation sequencing and big data to accelerate the progress of precision oncology treatment and new drug development. Together, we aim to provide more comprehensive and flexible solutions for anti-tumor drug research and development, ensuring that innovative technologies and products benefit a broader population of cancer patients.”

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (Tokyo Stock Exchange Code: 4502; New York Stock Exchange Code: TAK) is a global, research and development-driven pharmaceutical company committed to bringing better health for people and a brighter future for our planet. Headquartered in Japan, Takeda focuses its drug discovery efforts on four therapeutic areas: Oncology, Gastroenterology, Neuroscience, and Rare Diseases, with dedicated R&D investments in Plasma-Derived Therapies and Vaccines. We are committed to developing highly innovative medicines by exploring new treatment modalities and strengthening our collaborative R&D engine, thereby building a robust and diverse pipeline to improve patients’ lives. With employees in approximately 80 countries and regions, we work alongside local healthcare partners to deliver health benefits to patients worldwide.

Takeda entered China in 1994. Takeda China’s headquarters is located in Shanghai, with its main business centers on the Chinese mainland situated in cities such as Beijing, Shanghai, Tianjin, and Guangzhou, as well as in the Hong Kong Special Administrative Region. The company has established offices in major cities across China and currently employs more than 2,000 people in the country. With China’s economic development and the growing demand for healthcare, China has become one of Takeda’s most important emerging markets globally.

For more information, please visithttps://www.takeda.com

About OrigiMed

OrigiMed is a precision medicine company specializing in high-tech R&D and clinical application translation in the field of oncology. It operates CLIA- and CAP-accredited laboratories meeting international standards, with its business coverage extending to over 40 cities. OrigiMed is committed to providing precision medicine solutions for cancer patients and serves as a close partner to biopharmaceutical companies, accelerating their biomarker-driven drug development. By delivering comprehensive and accurate molecular-level information for each patient, OrigiMed matches them with relevant targeted therapies, immunotherapies, and clinical trials, thereby assisting physicians in precise diagnosis and treatment and driving innovation in the clinical management of cancer patients in China.

For more information, please visithttp://www.origimed.com

This article is published with authorization. The copyright belongs to the original author. The content represents the independent views of the author and does not reflect the position of EqualOcean. For reprinting, please contact the original author.